Open AccessPrevalence and Safety of COVID-19 Vaccination in Community-Dwelling People with Dementia: Findings from a Tertiary Memory Clinic in Italy
Author(s) -
Martina Valletta,
Marco Canevelli,
Fabrizia D’Antonio,
Alessandro Trebbastoni,
Giuseppina Talarico,
Alessandra Campanelli,
Micaela Sepe Monti,
Antonella Di Vita,
Emanuela Salati,
Letizia Imbriano,
Roberta Margiotta,
Sonia Barbetti,
Sofia Diana,
Simona Buscarnera,
Marco Toccaceli Blasi,
Martina Salzillo,
Giuseppe Pugliese,
Nicola Vanacore,
Giuseppe Bruno
Publication year - 2022
Publication title -
journal of alzheimer's disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.677
H-Index - 139
eISSN - 1875-8908
pISSN - 1387-2877
DOI - 10.3233/jad-220077
Subject(s) - vaccination , dementia , medicine , adverse effect , cognitive impairment , cognition , covid-19 , immunization , family medicine , psychiatry , immunology , disease , infectious disease (medical specialty) , antigen
This study aimed to explore the prevalence and safety of SARS-CoV-2 vaccination in individuals with dementia. Patients with mild cognitive impairment or dementia were recruited at a tertiary memory clinic, from March 15 to September 15, 2021. Information on COVID-19 vaccination and adverse events experienced after vaccine administration were collected from caregivers. Two-hundred-seventy subjects were finally recruited. Among them, 253 (93.7%) had received the vaccine and only 69 (27.3%) experienced adverse events. Cognitive and behavioral changes following immunization were only rarely reported. COVID-19 vaccination is safe and well-tolerated in patients with cognitive impairment who should be prioritized in the vaccination campaign.